Cargando…
Assessment of the proarrhythmic effects of repurposed antimalarials for COVID-19 treatment using a comprehensive in vitro proarrhythmia assay (CiPA)
Due to the outbreak of the SARS-CoV-2 virus, drug repurposing and Emergency Use Authorization have been proposed to treat the coronavirus disease 2019 (COVID-19) during the pandemic. While the efficiency of the drugs has been discussed, it was identified that certain compounds, such as chloroquine a...
Autores principales: | Yoon, Seung-Hyun, Lee, Hyun-Lee, Jeong, Da Un, Lim, Ki Moo, Park, Seong-Jun, Kim, Ki-Suk |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10464612/ https://www.ncbi.nlm.nih.gov/pubmed/37649890 http://dx.doi.org/10.3389/fphar.2023.1220796 |
Ejemplares similares
-
Introduction to in silico model for proarrhythmic risk assessment under the CiPA initiative
por: Park, Jin-Sol, et al.
Publicado: (2019) -
Assessment of an In Silico Mechanistic Model for Proarrhythmia Risk Prediction Under the CiPA Initiative
por: Li, Zhihua, et al.
Publicado: (2018) -
Testing the nonclinical Comprehensive In Vitro Proarrhythmia Assay (CiPA) paradigm with an established anti‐seizure medication: Levetiracetam case study
por: Delaunois, Annie, et al.
Publicado: (2023) -
General Principles for the Validation of Proarrhythmia Risk Prediction Models: An Extension of the CiPA In Silico Strategy
por: Li, Zhihua, et al.
Publicado: (2019) -
Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off‐label in the first wave of COVID‐19
por: Delaunois, Annie, et al.
Publicado: (2021)